Clinical Trial Update: A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating belzutifan in combination with cabozantinib for clear cell renal cell carcinoma; the MK-6482-003 study is currently active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• Welireg (belzutifan)

Snippet

Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING